Integrated Advisors Network LLC Has $655,000 Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Integrated Advisors Network LLC decreased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.6% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 7,811 shares of the biopharmaceutical company’s stock after selling 377 shares during the quarter. Integrated Advisors Network LLC’s holdings in Gilead Sciences were worth $655,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Diversify Advisory Services LLC acquired a new position in shares of Gilead Sciences during the 1st quarter worth approximately $316,000. Mission Wealth Management LP increased its holdings in shares of Gilead Sciences by 3.0% during the 1st quarter. Mission Wealth Management LP now owns 12,454 shares of the biopharmaceutical company’s stock worth $912,000 after acquiring an additional 368 shares during the last quarter. Resonant Capital Advisors LLC increased its holdings in shares of Gilead Sciences by 12.6% during the 1st quarter. Resonant Capital Advisors LLC now owns 3,050 shares of the biopharmaceutical company’s stock worth $223,000 after acquiring an additional 342 shares during the last quarter. Stone Point Wealth LLC grew its holdings in Gilead Sciences by 3.5% in the 1st quarter. Stone Point Wealth LLC now owns 35,472 shares of the biopharmaceutical company’s stock valued at $2,598,000 after buying an additional 1,214 shares in the last quarter. Finally, Fortem Financial Group LLC grew its holdings in Gilead Sciences by 17.9% in the 1st quarter. Fortem Financial Group LLC now owns 9,496 shares of the biopharmaceutical company’s stock valued at $696,000 after buying an additional 1,444 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on GILD shares. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $75.00 price objective on shares of Gilead Sciences in a report on Tuesday. Truist Financial upped their price objective on Gilead Sciences from $82.00 to $83.00 and gave the company a “hold” rating in a report on Thursday, August 15th. Evercore ISI raised Gilead Sciences to a “strong-buy” rating in a report on Friday, August 9th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Thursday, August 15th. Finally, Sanford C. Bernstein started coverage on Gilead Sciences in a report on Thursday, October 17th. They issued an “outperform” rating and a $105.00 price objective on the stock. Ten research analysts have rated the stock with a hold rating, eleven have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $86.85.

Gilead Sciences Price Performance

Shares of GILD stock opened at $88.82 on Friday. The company has a quick ratio of 0.95, a current ratio of 1.14 and a debt-to-equity ratio of 1.18. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $89.74. The company has a market cap of $110.66 billion, a P/E ratio of 246.72, a P/E/G ratio of 3.07 and a beta of 0.18. The business has a fifty day simple moving average of $83.54 and a 200 day simple moving average of $73.97.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.61 by $0.40. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. The business had revenue of $6.95 billion during the quarter, compared to the consensus estimate of $6.64 billion. On average, sell-side analysts forecast that Gilead Sciences, Inc. will post 3.76 EPS for the current fiscal year.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the completion of the transaction, the insider now directly owns 100,189 shares in the company, valued at approximately $8,398,843.87. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the completion of the transaction, the insider now directly owns 100,189 shares in the company, valued at approximately $8,398,843.87. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Johanna Mercier sold 5,490 shares of the stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total value of $406,150.20. Following the completion of the transaction, the insider now owns 114,979 shares of the company’s stock, valued at $8,506,146.42. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 36,847 shares of company stock worth $3,033,340. 0.16% of the stock is currently owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.